20 October 1986
INTERIM COMMERCIAL ITEM DESCRIPTION
THEOPHYLLINE CAPSULES, MODIFIED, SUSTAINED-RELEASE
The General Services Administration has authorized the use of this Interim Commercial Item Description which was developed by DLA, Defense Personnel Support Center, Directorate of Medical Materiel, DPSC-RST, 2800 South 20th Street, Philadelphia, PA 19101, based upon currently available technical information.
Shall be Anhydrous Theophylline Capsules, Modified, Sustained-Release.
For Strength 1, shall contain 100 mg of Anhydrous Theophylline per capsule, within the applicable assay limits for the capsules.
For Strength 2, shall contain 200 mg of Anhydrous Theophylline per capsule, within the applicable assay limits for the capsules.
For Strength 3, shall contain 300 mg of Anhydrous Theophylline per capsule, within the applicable assay limits for the capsules.
The capsules must be considered by the FDA to be therapeutically equivalent with Anhydrous Theophylline Capsules by Searle Laboratories at the same dosage and administration schedule.
Workmanship. The capsules shall be free from defects which detract from their appearance or impair their serviceability.
Unit. Bottle (BT). One bottle containing 100 capsules, as specified, constitutes one unit.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business